Iron Status and Supplementation during Tuberculosis.
Arista NienaberMary A UyogaRobin Claire Dolman-MacleodLinda MalanPublished in: Microorganisms (2023)
Tuberculosis (TB) is characterised by chronic non-resolving inflammation. The effects of the host immune and inflammatory response to reduce iron acquisition by the bacteria, together with other contributing factors, predispose TB patients to anaemia of infection and iron deficiency anaemia (IDA). The presence of anaemia in TB patients has been linked to poor clinical outcomes. However, due to the reliance of the bacteria on iron, the management of anaemia in TB is complicated, and anaemia of infection is likely to resolve with correct TB drug treatment. On the other hand, IDA may require iron supplementation. This review aims to describe iron metabolism in TB and how this contributes to the development of iron deficiency and anaemia. Additionally, we summarise the evidence on the association between iron status and clinical outcomes as well as the available preclinical and clinical trials on iron supplementation in TB.
Keyphrases
- iron deficiency
- mycobacterium tuberculosis
- end stage renal disease
- clinical trial
- ejection fraction
- inflammatory response
- newly diagnosed
- chronic kidney disease
- oxidative stress
- pulmonary tuberculosis
- peritoneal dialysis
- mesenchymal stem cells
- emergency department
- randomized controlled trial
- patient reported outcomes
- bone marrow
- lipopolysaccharide induced
- toll like receptor
- study protocol
- hepatitis c virus